Skip to main
ALT
ALT logo

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc's pemvidutide has demonstrated significant clinical efficacy, notably achieving up to a 76% reduction in liver fat and improvements in key biomarkers associated with liver inflammation and fibrosis, which bodes well for its potential in treating metabolic-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD). The favorable tolerability profile of pemvidutide compared to existing therapies enhances its attractiveness as a treatment option, while its unique dual mechanism of action supports its capability to address systemic metabolic dysfunction effectively. Additionally, the FDA's openness to non-invasive endpoints could expedite the regulatory approval process, further strengthening the company's position in the biopharmaceutical landscape.

Bears say

Altimmune Inc reported a net loss of $23.2 million in the fourth quarter of 2024, indicating ongoing financial challenges as the company continues its clinical development for pemvidutide. Despite pemvidutide's promising weight loss results—showing an average of 15.6% body weight reduction—the market adoption of other approved treatments suggests significant hurdles driven by poor tolerability, compliance issues, and limited efficacy. Furthermore, the company faces multiple risks, including clinical development and commercialization challenges, potential competitor threats, and external factors such as geopolitical disruptions and the ongoing impact of COVID-19, which could adversely affect its financial stability and growth prospects.

Altimmune (ALT) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 13 analysts, Altimmune (ALT) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.